Human papilloma virus in oral cancer

키워드

참고문헌 (77)

1. Ju Rim Sun, "Oral cancer incidence based on annual cancer statistics in Korea", 대한구강악안면외과학회지, 38(1), pp.20~28 (2012), 대한구강악안면외과학회
2. Forman D, "Cancer incidence in five continents Vol. X" (2014), IARC
3. Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J Pathol, 189, pp.12~19 (1999)
4. van der Marel J, "Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?", Am J Surg Pathol, 39, pp.496~504 (2015)
5. Bosch FX, "The causal relation between human papillomavirus and cervical cancer", J Clin Pathol, 55, pp.244~265 (2002)
6. Muñoz N, "Epidemiologic classification of human papillomavirus types associated with cervical cancer", N Engl J Med, 348, pp.518~527 (2003)
7. de Villiers EM, "Classification of papillomaviruses", Virology, 324, pp.17~27 (2004)
8. Buck CB, "Arrangement of L2 within the papillomavirus capsid", J Virol, 82, pp.5190~5197 (2008)
9. zur Hausen H, "Papillomaviruses and cancer: from basic studies to clinical application", Nat Rev Cancer, 2, pp.342~350 (2002)
10. Rautava J, "Biology of human papillomavirus infections in head and neck carcinogenesis", Head Neck Pathol, 6(Suppl 1), pp.S3~15 (2012)
11. Lizano M, "HPV-related carcinogenesis:basic concepts, viral types and variants", Arch Med Res, 40, pp.428~434 (2009)
12. Cardoso JC, "Cutaneous manifestations of human papillomaviruses:a review", Acta Dermatovenerol Alp Pannonica Adriat, 20, pp.145~154 (2011)
13. Orth G, "Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis", Curr Top Microbiol Immunol, 321, pp.59~83 (2008)
14. Lazarczyk M, "The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections", Microbiol Mol Biol Rev, 73, pp.348~370 (2009)
15. Stoler MH, "Human papillomaviruses and cervical neoplasia: a model for carcinogenesis", Int J Gynecol Pathol, 19, pp.16~28 (2000)
16. Kreimer AR, "Human papillomavirus types in head and neck squamous cell carcinomas worldwide:a systematic review", Cancer Epidemiol Biomarkers Prev, 14, pp.467~475 (2005)
17. Miralles-Guri C, "Human papillomavirus prevalence and type distribution in penile carcinoma", J Clin Pathol, 62, pp.870~878 (2009)
18. Campisi G, "Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review)", Int J Oncol, 30, pp.813~823 (2007)
19. Femiano F, "Papilloma virus. Review of the literature. Note II. Diagnosis and treatment", Minerva Stomatol, 49, pp.179~186 (2000)
20. Miller CS, "Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 91, pp.622~635 (2001)
21. Syrjänen K, "Factors associated with progression of cervical human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up", Br J Obstet Gynaecol, 95, pp.1096~1102 (1988)
22. Pfister H, "Human papillomaviruses and skin cancer", Semin Cancer Biol, 3, pp.263~271 (1992)
23. Münger K, "Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product", EMBO J, 8, pp.4099~4105 (1989)
24. Werness BA, "Association of human papillomavirus types 16 and 18 E6 proteins with p53", Science, 248, pp.76~79 (1990)
25. Santoro V, "Role of human papilloma virus in precancerous and cancerous lesions of the oral cavity. Review of the literature", Minerva Stomatol, 46, pp.595~601 (1997)
26. Fornatora ML, "It's time to modernize our approach to oral HPV lesions", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 91, pp.494~496 (2001)
27. 박민우, "Focal epithelial hyperplasia arising after delivery of metal-ceramic fixed dental prosthesis", The Journal of Advanced of Prosthodontics, 6(6), pp.555~558 (2014), 대한치과보철학회[DOI]
28. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, "IARC monographs on the evaluation of carcinogenic risks to humans, A review of human carcinogens. B. Biological agents", pp.278~280 (2012), International Agency for Research on Cancer
29. Fakhry C, "Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial", J Natl Cancer Inst, 100, pp.261~269 (2008)
30. Dayyani F, "Metaanalysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)", Head Neck Oncol, 2, pp.15~ (2010)
31. Bouda M, ""High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa", Mod Pathol, 13, pp.644~653 (2000)
32. Kojima A, "Human papillomavirus type 38 infection in oral squamous cell carcinomas", Oral Oncol, 38, pp.591~596 (2002)
33. Kim KS, "Current status of human papillomavirus vaccines", Clin Exp Vaccine Res, 3, pp.168~175 (2014)
34. Snow AN, "Human papillomavirus detection in head and neck squamous cell carcinomas", Adv Anat Pathol, 17, pp.394~403 (2010)
35. Gillison ML, "Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers", J Natl Cancer Inst, 100, pp.407~420 (2008)
36. Heck JE, "Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium", Int J Epidemiol, 39, pp.166~181 (2010)
37. Lajer CB, "The role of human papillomavirus in head and neck cancer", APMIS, 118, pp.510~519 (2010)
38. Mishra R, "Biomarkers of oral premalignant epithelial lesions for clinical application", Oral Oncol, 48, pp.578~584 (2012)
39. Napier SS, "Natural history of potentially malignant oral lesions and conditions: an overview of the literature", J Oral Pathol Med, 37, pp.1~10 (2008)
40. Villa A, "Oral cancer and oral erythroplakia: an update and implication for clinicians", Aust Dent J, 56, pp.253~256 (2011)
41. Greer RO Jr, "Is p16(INK4a) protein expression in oral ST lesions a reliable precancerous marker?", Int J Oral Maxillofac Surg, 37, pp.840~846 (2008)
42. Leemans CR, "The molecular biology of head and neck cancer", Nat Rev Cancer, 11, pp.9~22 (2011)
43. Feller L, "Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma", Head Face Med, 6, pp.15~ (2010)
44. Markowitz LE, "Human papillomavirus vaccine introduction--the first five years", Vaccine, 30(Suppl 5), pp.F139~148 (2012)
45. Castle PE, "Prophylactic HPV vaccination: past, present, and future", Epidemiol Infect, 144, pp.449~468 (2016)
46. zur Hausen H, "Human papilloma viruses and cancer", Bibl Haematol, 43, pp.569~571 (1975)
47. Zhou J, "Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles", Virology, 185, pp.251~257 (1991)
48. Baker TS, "Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction", Biophys J, 60, pp.1445~1456 (1991)
49. zur Hausen H, "Papillomaviruses in the causation of human cancers:a brief historical account", Virology, 384, pp.260~265 (2009)
50. Kumaraswamy KL, "Human papilloma virus and oral infections: an update", J Cancer Res Ther, 7, pp.120~127 (2011)
51. Syrjänen KJ, "Immunohistochemical demonstration of human papilloma virus (HPV)antigens in oral squamous cell lesions", Br J Oral Surg, 21, pp.147~153 (1983)
52. Cox MF, "Viruses in the aetiology of oral carcinoma? Examination of the evidence", Br J Oral Maxillofac Surg, 29, pp.381~387 (1991)
53. Murray M, "Progress in preventing cervical cancer: updated evidence on vaccination and screening", Outlook, 27(2) (2010), Program for Appropriate Technology in Health (PATH)
54. "Recommended adult immunization schedule--United States, 2012" (2012)[URL]
55. Palefsky JM, "HPV vaccine against anal HPV infection and anal intraepithelial neoplasia", N Engl J Med, 365, pp.1576~1585 (2011)
56. Huygen F, "Investigating reports of complex regional pain syndrome: an analysis of HPV-16", 18-adjuvanted vaccine postlicensure data, 2015, pp.2, 1114~1121
57. Garçon N, "GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives", Expert Rev Vaccines, 6, pp.723~739 (2007)
58. Kash N, "Safety and efficacy data on vaccines and immunization to human papillomavirus", J Clin Med, 4, pp.614~633 (2015)
59. "HPV vaccines: promise and challenges"[URL]
60. Haupt RM, "The efficacy and safety of the quadrivalent human papillomavirus 6", 11, 18 vaccine gardasil, pp.J Adolesc Health, 2011[DOI]
61. McNeil C, "Who invented the VLP cervical cancer vaccines?", J Natl Cancer Inst, 98, pp.433~ (2006)
62. Shi L, "GARDASIL:prophylactic human papillomavirus vaccine development:from bench top to bed-side", Clin Pharmacol Ther, 81, pp.259~264 (2007)
63. Vichnin M, "An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015", Pediatr Infect Dis J, 34, pp.983~991 (2015)
64. Slade BA, "Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine", JAMA, 302, pp.750~757 (2009)
65. Garland SM, "Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine", Vaccine, 33, pp.6855~6864 (2015)
66. Labadie J, "Postlicensure safety evaluation of human papilloma virus vaccines", Int J Risk Saf Med, 23, pp.103~112 (2011)
67. Brotherton JM, "Current status of human papillomavirus vaccination", Curr Opin Oncol, 27, pp.399~404 (2015)
68. Brisson M, "Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States", J Natl Cancer Inst (2015)[DOI]
69. Bazan SB, "Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris", Arch Virol, 154, pp.1609~1617 (2009)
70. Rybicki EP, "Vaccine farming in Cape Town", Hum Vaccin, 7, pp.339~348 (2011)
71. Majewski S, "Immunology of HPV infection and HPVassociated tumors", Int J Dermatol, 37, pp.81~95 (1998)
72. Chang F, "Role of papillomaviruses", J Clin Pathol, 43, pp.269~276 (1990)
73. Tindle RW, "Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation", Curr Top Microbiol Immunol, 186, pp.217~253 (1994)
74. Arya SC, "Extended coverage of HPV vaccination in middle-aged adults to prevent oropharyngeal cancers", Hum Vaccin Immunother, 8, pp.959~ (2012)
75. Ramqvist T, "An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention", Anticancer Res, 31, pp.1515~1519 (2011)
76. Matsushita K, "Oral and cervical human papillomavirus infection among female sex workers in Japan", Jpn J Infect Dis, 64, pp.34~39 (2011)
77. Zil-A-Rubab, "Human papilloma virus--role in precancerous and cancerous oral lesions of tobacco chewers", J Pak Med Assoc, 63, pp.1295~1298 (2013)

관련 논문AI추천